Using transient co-expression assays in colon cancer-derived HCT116, Nahor et al. showed that both proteins inhibit the IGF-1R promoter reducing endogenous IGF-1R levels in a dose-dependent manner. This evidence concerns the gene IGF1R and malignant colon neoplasm.